ArticlePloS one2016
Prevalence of Neutralizing Antibodies to Japanese Encephalitis Virus among High-Risk Age Groups in South Korea, 2010.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Seroprevalence of Japanese Encephalitis Virus, and Immunogenicity of the Vero-Cell Culture-Derived Vaccine in Hematopoietic Stem Cell Transplantation Recipients.Journal of Korean medical science · 2026Article
- A Serosurvey of Japanese Encephalitis Virus in Monkeys and Humans Living in Proximity in Thailand.Viruses · 2023Article
- Japanese Encephalitis among Adults: A Review.The American journal of tropical medicine and hygiene · 2023Review
- Japanese Encephalitis Virus-Infected Cells.Sub-cellular biochemistry · 2023Article
- The reemerging and outbreak of genotypes 4 and 5 of Japanese encephalitis virus.Frontiers in cellular and infection microbiology · 2023Review
- Emerging Japanese Encephalitis Virus Genotype V in Republic of Korea.Journal of microbiology and biotechnology · 2022Review
- Seroepidemiological study of Japanese encephalitis virus in Chiang Mai: Immunity and susceptibility 28 years after introduction of a vaccination programme.PLoS neglected tropical diseases · 2022Article
- Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea.Clinical and experimental pediatrics · 2022Article
- Seroepidemiological Studies on Japanese Encephalitis: A Systematic Review.Oman medical journal · 2022Review
- Importance of maintaining a high childhood vaccination rate and surveillance program against Japanese encephalitis in Korea.Clinical and experimental pediatrics · 2022Article
- The current burden of Japanese encephalitis and the estimated impacts of vaccination: Combining estimates of the spatial distribution and transmission intensity of a zoonotic pathogen.PLoS neglected tropical diseases · 2021Article
- Long-Term Neurological Sequelae and Disease Burden of Japanese Encephalitis in Gansu Province, China.Annals of global health · 2021Article
- Article
- Genetic Characterization of Japanese Encephalitis Virus Genotype 5 Isolated from Patient, South Korea, 2015.Emerging infectious diseases · 2020Article
- Review of the Incidence of Japanese Encephalitis in Foreign-Born and Korean Nationals Living in the Republic of Korea, 2007-2016.Osong public health and research perspectives · 2018Article
- Changes of Epidemiological Characteristics of Japanese Encephalitis Viral Infection and Birds as a Potential Viral Transmitter in Korea.Journal of Korean medical science · 2018Article
- Clinical Characteristics of Severe Japanese Encephalitis: A Case Series from South Korea.The American journal of tropical medicine and hygiene · 2017Article
- Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Human vaccines & immunotherapeutics · 2017Review
- Reemergence of Japanese Encephalitis in South Korea, 2010-2015.Emerging infectious diseases · 2016Article
- Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.PLoS neglected tropical diseases · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After an extensive vaccination policy, Japanese encephalitis (JE) was nearly eliminated since the mid-1980s in South Korea. Vaccination in children shifted the affected age of JE patients from children to adults. However, an abrupt increase in JE cases occurred in 2010, and this trend has continued. The present study aimed to investigate the prevalence of neutralizing antibodies to the JE virus (JEV) among high-risk age groups (≥40 years) in South Korea. A plaque reduction neutralization test was conducted to evaluate the prevalence of neutralizing antibodies to JEV in 945 subjects within four age groups (30-39, 40-49, 50-59, and 60-69 years) in 10 provinces. Of the 945 enrolled subjects, 927 (98.1%) exhibited antibodies against JEV. No significant differences were found in the prevalence of neutralizing antibodies according to sex, age, or occupation. However, there were significant differences in the plaque reduction rate according to age and occupation; oldest age group had a higher reduction rate, and subjects who were employed in agriculture or forestry also had a higher value than the other occupations. We also found that three provinces (Gangwon, Jeonnam, and Gyeongnam) had a relatively lower plaque reduction rate than the other locations. In addition, enzyme-linked immunosorbent assays were conducted to determine recent viral infections and 12 (1.3%) subjects were found to have been recently infected by the virus [corrected]. In conclusion, the present study clearly indicated that the prevalence of neutralizing antibodies has been maintained at very high levels among adult age groups owing to vaccination or natural infections, or both. In the future, serosurveillance should be conducted periodically using more representative samples to better understand the population-level immunity to JE in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.